Biology of diabetic neuropathy

Handbook of Clinical Neurology

Volumn 115, Issue , 2013, Pages 591-606

  Vincent, Andrea M ^a   Calabek, Bernadette ^b   Roberts, Laurel ^a   Feldman, Eva L ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b KAISER FRANZ JOSEF HOSPITAL   (Austria)

Author keywords

Epigenetics; Glucose; Inflammation; Lipids; Metabolic mechanisms; Oxidative stress; Peripheral neuropathy; Polyneuropathy; Treatment

Indexed keywords

GLUCOSE; INSULIN; LIPID;

ARTICLE; BIOLOGY; DIABETIC NEUROPATHY; EPIGENETICS; HUMAN; INFLAMMATION; METABOLIC MECHANISMS; METABOLISM; NERVE CONDUCTION; OXIDATIVE STRESS; PATHOLOGY; PATHOPHYSIOLOGY; PERIPHERAL NERVE; PERIPHERAL NEUROPATHY; PHYSIOLOGY; POLYNEUROPATHY; TREATMENT;

EPIGENETICS; GLUCOSE; INFLAMMATION; LIPIDS; METABOLIC MECHANISMS; OXIDATIVE STRESS; PERIPHERAL NEUROPATHY; POLYNEUROPATHY; TREATMENT;

BIOLOGY; DIABETIC NEUROPATHIES; HUMANS; INSULIN; NEURAL CONDUCTION; OXIDATIVE STRESS; PERIPHERAL NERVES;

EID: 84881489496     PISSN: 00729752     EISSN: None     Source Type: Book Series    
DOI: 10.1016/B978-0-444-52902-2.00034-5     Document Type: Chapter

References (177)

1. Aiello L.P., Davis M.D., Girach A., et al. Effect of ruboxistaurin on visual loss in patients with diabetic retinopathy. Ophthalmology 2006, 113:2221-2230.
2. Albers J.W., Brown M.B., Sima A.A., et al. Nerve conduction measures in mild diabetic neuropathy in the Early Diabetes Intervention Trial: the effects of age, sex, type of diabetes, disease duration, and anthropometric factors. Tolrestat Study Group for the Early Diabetes Intervention Trial. Neurology 1996, 46:85-91.
3. Andreassen C.S., Jakobsen J., Flyvbjerg A., et al. Expression of neurotrophic factors in diabetic muscle: relation to neuropathy and muscle strength. Brain 2009, 132:2724-2733.
4. Apfel S.C. Neurotrophic factors in peripheral neuropathies: therapeutic implications. Brain Pathol 1999, 9:393-413.
5. Apfel S.C. Nerve growth factor for the treatment of diabetic neuropathy: what went wrong, what went right, and what does the future hold?. Int Rev Neurobiol 2002, 50:393-413.
6. Arenas J., Rubio J.C., Martin M.A., et al. Biological roles of L-carnitine in perinatal metabolism. Early Hum Dev 1998, 53:S43-S50.
7. Arezzo J.C., Zotova E. Electrophysiologic measures of diabetic neuropathy: mechanism and meaning. Int Rev Neurobiol 2002, 50:229-255.
8. Arias C., Becerra-Garcia F., Tapia R., et al. Glutamic acid and Alzheimer's disease. Neurobiology (Bp) 1998, 6:33-43.
9. Asbury A.K., Porte D., Genuth S.M., et al. Diabetes Care 1988, 11:592-597.
10. Asif M., Egan J., Vasan S., et al. An advanced glycation endproduct cross-link breaker can reverse age-related increases in myocardial stiffness. Proc Natl Acad Sci U S A 2000, 97:2809-2813.
11. Audeh M.W., Carmichael J., Penson R.T., et al. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial. Lancet 2010, 376:245-251.
12. Avignon A., Sultan A. PKC-B inhibition: a new therapeutic approach for diabetic complications?. Diabetes Metab 2006, 32:205-213.
13. Begon S., Pickering G., Eschalier A., et al. Magnesium and MK-801 have a similar effect in two experimental models of neuropathic pain. Brain Res 2000, 887:436-439.
14. Boulton A.J. Lowering the risk of neuropathy, foot ulcers and amputations. Diabet Med 1998, 15:S57-S59.
15. Britland S.T., Young R.J., Sharma A.K., et al. Association of painful and painless diabetic polyneuropathy with different patterns of nerve fiber degeneration and regeneration. Diabetes 1990, 39:898-908.
16. Brownlee M. Advanced protein glycosylation in diabetes and aging. Annu Rev Med 1995, 46:223-234.
17. Buse M.G. Hexosamines, insulin resistance, and the complications of diabetes: current status. Am J Physiol Endocrinol Metab 2006, 290:E1-E8.
18. Cameron N.E., Cotter M.A. Effects of antioxidants on nerve and vascular dysfunction in experimental diabetes. Diabetes Res Clin Pract 1999, 45:137-146.
19. Casellini C.M., Barlow P.M., Rice A.L., et al. A 6-month, randomized, double-masked, placebo-controlled study evaluating the effects of the protein kinase C-beta inhibitor ruboxistaurin on skin microvascular blood flow and other measures of diabetic peripheral neuropathy. Diabetes Care 2007, 30:896-902.
20. Chen S.R., Samoriski G., Pan H.L., et al. Antinociceptive effects of chronic administration of uncompetitive NMDA receptor antagonists in a rat model of diabetic neuropathic pain. Neuropharmacology 2009, 57:121-126.
21. Cheng H.T., Dauch J.R., Hayes J.M., et al. Nerve growth factor mediates mechanical allodynia in a mouse model of type 2 diabetes. J Neuropathol Exp Neurol 2009, 68:1229-1243.
22. Cheng H.T., Dauch J.R., Oh S.S., et al. p38 mediates mechanical allodynia in a mouse model of type 2 diabetes. Mol Pain 2010, 6:28.
23. Cheng C., Zochodne D.W. Sensory neurons with activated caspase-3 survive long-term experimental diabetes. Diabetes 2003, 52:2363-2371.
24. Cheriyan J., Webb A.J., Sarov-Blat L., et al. Inhibition of p38 mitogen-activated protein kinase improves nitric oxide-mediated vasodilatation and reduces inflammation in hypercholesterolemia. Circulation 2010, 123:515-523.
25. Choudhury D., Tuncel M., Levi M., et al. Diabetic nephropathy: a multifaceted target of new therapies. Discov Med 2010, 10:406-415.
26. Chowdhury T.A., Kumar S., Barnett A.H., et al. Nephropathy in type 1 diabetes: the role of genetic factors. Diabet Med 1995, 12:1059-1067.
27. Chu Q., Moreland R., Yew N.S., et al. Systemic insulin-like growth factor-1 reverses hypoalgesia and improves mobility in a mouse model of diabetic peripheral neuropathy. Mol Ther 2008, 16:1400-1408.
28. Chung S.S., Chung S.K. Genetic analysis of aldose reductase in diabetic complications. Curr Med Chem 2003, 10:1375-1387.
29. Collier A., Small M. The role of the polyol pathway in diabetes mellitus. Br J Hosp Med 1991, 45:38-40.
30. Cotter M.A., Ekberg K., Wahren J., et al. Effects of proinsulin C-peptide in experimental diabetic neuropathy: vascular actions and modulation by nitric oxide synthase inhibition. Diabetes 2003, 52:1812-1817.
31. Cvrcek P. Side effects of ketamine in the long-term treatment of neuropathic pain. Pain Med 2008, 9:253-257.
32. Das Evcimen N., King G.L. The role of protein kinase C activation and the vascular complications of diabetes. Pharmacol Res 2007, 55:498-510.
33. Daulhac L., Mallet C., Courteix C., et al. Diabetes-induced mechanical hyperalgesia involves spinal mitogen-activated protein kinase activation in neurons and microglia via N-methyl-D-aspartate-dependent mechanisms. Mol Pharmacol 2006, 70:1246-1254.
34. DCCT-Research-Group Factors in development of diabetic neuropathy. Baseline analysis of neuropathy in feasibility phase of Diabetes Control and Complications Trial (DCCT). The DCCT Research Group. Diabetes 1988, 37:476-481.
35. de Murcia G., Schreiber V., Molinete M., et al. Structure and function of poly(ADP-ribose) polymerase. Mol Cell Biochem 1994, 138:15-24.
36. De Palo E., Gatti R., Sicolo N., et al. Plasma and urine free L-carnitine in human diabetes mellitus. Acta Diabetol Lat 1981, 18:91-95.
37. de Rekeneire N., Peila R., Ding J., et al. Diabetes, hyperglycemia, and inflammation in older individuals: the health, aging and body composition study. Diabetes Care 2006, 29:1902-1908.
38. Del Prato S. Loss of early insulin secretion leads to postprandial hyperglycaemia. Diabetologia 2003, 46:M2-M8.
39. Dey D., Basu D., Roy S.S., et al. Involvement of novel PKC isoforms in FFA induced defects in insulin signaling. Mol Cell Endocrinol 2006, 246:60-64.
40. Di Cesare Mannelli L., Ghelardini C., Toscano A., et al. The neuropathy-protective agent acetyl-L-carnitine activates protein kinase C-gamma and MAPKs in a rat model of neuropathic pain. Neuroscience 2010, 165:1345-1352.
41. Dobretsov M., Hastings S.L., Romanovsky D., et al. Mechanical hyperalgesia in rat models of systemic and local hyperglycemia. Brain Res 2003, 960:174-183.
42. Drory V.E., Groozman G.B., Rubinstein A., et al. Hypertriglyceridemia may cause a subclinical peripheral neuropathy. Electromyogr Clin Neurophysiol 1999, 39:39-41.
43. Du X.L., Edelstein D., Rossetti L., et al. Hyperglycemia-induced mitochondrial superoxide overproduction activates the hexosamine pathway and induces plasminogen activator inhibitor-1 expression by increasing Sp1 glycosylation. Proc Natl Acad Sci U S A 2000, 97:12222-12226.
44. Dyck P.J., Giannini C. Pathologic alterations in the diabetic neuropathies of humans: a review. J Neuropathol Exp Neurol 1996, 55:1181-1193.
45. Edwards J.L., Vincent A.M., Cheng H.T., et al. Diabetic neuropathy: mechanisms to management. Pharmacol Ther 2008, 120:1-34.
46. Ejskjaer N.T., Zanone M.M., Peakman M., et al. Autoimmunity in diabetic autonomic neuropathy: does the immune system get on your nerves?. Diabet Med 1998, 15:723-729.
47. Evans J.D., Jacobs T.F., Evans E.W., et al. Role of acetyl-L-carnitine in the treatment of diabetic peripheral neuropathy. Ann Pharmacother 2008, 42:1686-1691.
48. Gao X., Zhang H., Schmidt A.M., et al. AGE/RAGE produces endothelial dysfunction in coronary arterioles in type 2 diabetic mice. Am J Physiol Heart Circ Physiol 2008, 295:H491-H498.
49. Gibson T.M., Cotter M.A., Cameron N.E., et al. Effects of poly(ADP-ribose) polymerase inhibition on dysfunction of non-adrenergic non-cholinergic neurotransmission in gastric fundus in diabetic rats. Nitric Oxide 2006, 15:344-350.
50. Goto Y., Hotta N., Shigeta Y., et al. A placebo-controlled double-blind study of epalrestat (ONO-2235) in patients with diabetic neuropathy. Diabet Med 1993, 10:39S-43S.
51. Granberg V., Ejskjaer N., Peakman M., et al. Autoantibodies to autonomic nerves associated with cardiac and peripheral autonomic neuropathy. Diabetes Care 2005, 28:1959-1964.
52. Grandinetti A., Chow D.C., Sletten D.M., et al. Impaired glucose tolerance is associated with postganglionic sudomotor impairment. Clin Auton Res 2007, 17:231-233.
53. Green A.Q., Krishnan S., Finucane F.M., et al. Altered C-fiber function as an indicator of early peripheral neuropathy in individuals with impaired glucose tolerance. Diabetes Care 2010, 33:174-176.
54. Greene D.A., Sima A.A., Stevens M.J., et al. Complications: neuropathy, pathogenetic considerations. Diabetes Care 1992, 15:1902-1925.
55. Heald A.H., Anderson S.G., Ivison F., et al. C-reactive protein and the insulin-like growth factor (IGF)-system in relation to risk of cardiovascular disease in different ethnic groups. Atherosclerosis 2003, 170:79-86.
56. Ho E., Bray T.M. Antioxidants, NFkappaB activation, and diabetogenesis. Proc Soc Exp Biol Med 1999, 222:205-213.
57. Hobson M.I., Green C.J., Terenghi G., et al. VEGF enhances intraneural angiogenesis and improves nerve regeneration after axotomy. J Anat 2000, 197:591-605.
58. Homo-Delarche F. Immune cells: actors in pancreas development and regeneration that fail to fulfill their role and lead to diabetes?. Discov Med 2004, 4:344-350.
59. Hong S., Morrow T.J., Paulson P.E., et al. Early painful diabetic neuropathy is associated with differential changes in tetrodotoxin-sensitive and -resistant sodium channels in dorsal root ganglion neurons in the rat. J Biol Chem 2004, 279:29341-29350.
60. Hotta N. New concepts and insights on pathogenesis and treatment of diabetic complications: polyol pathway and its inhibition. Nagoya J Med Sci 1997, 60:89-100.
61. Irvine S.A., Foka P., Rogers S.A., et al. A critical role for the Sp1-binding sites in the transforming growth factor-beta-mediated inhibition of lipoprotein lipase gene expression in macrophages. Nucleic Acids Res 2005, 33:1423-1434.
62. Ishii H., Koya D., King G.L., et al. Protein kinase C activation and its role in the development of vascular complications in diabetes mellitus. J Mol Med 1998, 76:21-31.
63. Issad T., Kuo M. O-GlcNAc modification of transcription factors, glucose sensing and glucotoxicity. Trends Endocrinol Metab 2008, 19:380-389.
64. Jaeger C., Allendorfer J., Hatziagelaki E., et al. Persistent GAD 65 antibodies in longstanding IDDM are not associated with residual beta-cell function, neuropathy or HLA-DR status. Horm Metab Res 1997, 29:510-515.
65. Kawakami T., Kawakami Y., Kitaura J., et al. Protein kinase C beta (PKC beta): normal functions and diseases. J Biochem (Tokyo) 2002, 132:677-682.
66. Kihara M., Schmelzer J.D., Poduslo J.F., et al. Aminoguanidine effects on nerve blood flow, vascular permeability, electrophysiology, and oxygen free radicals. Proc Natl Acad Sci U S A 1991, 88:6107-6111.
67. Kiley S.C., Welsh J., Narvaez C.J., et al. Protein kinase C isozymes and substrates in mammary carcinogenesis. J Mammary Gland Biol Neoplasia 1996, 1:177-187.
68. Kitamura T., Kimura K., Makondo K., et al. Proinsulin C-peptide increases nitric oxide production by enhancing mitogen-activated protein-kinase-dependent transcription of endothelial nitric oxide synthase in aortic endothelial cells of Wistar rats. Diabetologia 2003, 46:1698-1705.
69. Kumar S., Arun K.H., Kaul C.L., et al. Effects of adenosine and adenosine A2A receptor agonist on motor nerve conduction velocity and nerve blood flow in experimental diabetic neuropathy. Neurol Res 2005, 27:60-66.
70. LeBlanc B.W., Iwata M., Mallon A.P., et al. A cyclic peptide targeted against PSD-95 blocks central sensitization and attenuates thermal hyperalgesia. Neuroscience 2010, 167:490-500.
71. Lechin F., van der Dijs B., Hernandez-Adrian G., et al. Dorsal raphe vs. median raphe serotonergic antagonism. Anatomical, physiological, behavioral, neuroendocrinological, neuropharmacological and clinical evidences: relevance for neuropharmacological therapy. Prog Neuropsychopharmacol Biol Psychiatry 2006, 30:565-585.
72. Lechin F., van der Dijs B., Pardey-Maldonado B., et al. Effects of amantadine on circulating neurotransmitters in healthy subjects. J Neural Transm 2010, 117:293-299.
73. Leinninger G.M., Backus C., Sastry A.M., et al. Mitochondria in DRG neurons undergo hyperglycemic mediated injury through Bim, Bax and the fission protein Drp1. Neurobiol Dis 2006, 23:11-22.
74. Leiter L.A. The prevention of diabetic microvascular complications of diabetes: is there a role for lipid lowering?. Diabetes Res Clin Pract 2005, 68:S3-S14.
75. Lestienne P., Bataille N. Mitochondrial DNA alterations and genetic diseases: a review. Biomed Pharmacother 1994, 48:199-214.
76. Li Q., Hwang Y.C., Ananthakrishnan R., et al. Polyol pathway and modulation of ischemia-reperfusion injury in Type 2 diabetic BBZ rat hearts. Cardiovasc Diabetol 2008, 7:33.
77. Li N., Young M.M., Bailey C.J., et al. NMDA and AMPA glutamate receptor subtypes in the thoracic spinal cord in lean and obese-diabetic ob/ob mice. Brain Res 1999, 849:34-44.
78. Lim K., Chang H.I. O-GlcNAc inhibits interaction between Sp1 and sterol regulatory element binding protein 2. Biochem Biophys Res Commun 2010, 393:314-318.
79. Liu Y., Gutterman D.D. The coronary circulation in diabetes: influence of reactive oxygen species on K+channel-mediated vasodilation. Vascul Pharmacol 2002, 38:43-49.
80. Low P.A., Lagerlund T.D., McManis P.G., et al. Nerve blood flow and oxygen delivery in normal, diabetic, and ischemic neuropathy. Int Rev Neurobiol 1989, 31:355-438.
81. Lupachyk S., Shevalye H., Maksimchyk Y., et al. PARP inhibition alleviates diabetes-induced systemic oxidative stress and neural tissue 4-hydroxynonenal adduct accumulation: Correlation with peripheral nerve function. Free Radic Biol Med 2011, 50:1400-1409.
82. Malik R.A., Williamson S., Abbott C., et al. Effect of angiotensin-converting-enzyme (ACE) inhibitor trandolapril on human diabetic neuropathy: randomised double-blind controlled trial. Lancet 1998, 352:1978-1981.
83. Martin L.J., Al-Abdulla N.A., Brambrink A.M., et al. Neurodegeneration in excitotoxicity, global cerebral ischemia, and target deprivation: a perspective on the contributions of apoptosis and necrosis. Brain Res Bull 1998, 46:281-309.
84. Masutani M., Nozaki T., Wakabayashi K., et al. Role of poly(ADP-ribose) polymerase in cell-cycle checkpoint mechanisms following gamma-irradiation. Biochimie 1995, 77:462-465.
85. Matsunaga A., Kawamoto M., Shiraishi S., et al. Intrathecally administered COX-2 but not COX-1 or COX-3 inhibitors attenuate streptozotocin-induced mechanical hyperalgesia in rats. Eur J Pharmacol 2007, 554:12-17.
86. Miyauchi Y., Shikama H., Takasu T., et al. Slowing of peripheral motor nerve conduction was ameliorated by aminoguanidine in streptozocin-induced diabetic rats. Eur J Endocrinol 1996, 134:467-473.
87. Monnier V.M., Glomb M., Elgawish A., et al. The mechanism of collagen cross-linking in diabetes: a puzzle nearing resolution. Diabetes 1996, 45:S67-S72.
88. Morcos M., Sayed A.A., Bierhaus A., et al. Activation of tubular epithelial cells in diabetic nephropathy. Diabetes 2002, 51:3532-3544.
89. Newfield R.S., Cohen D., Capparelli E.V., et al. Rapid weight gain in children soon after diagnosis of type 1 diabetes: is there room for concern?. Pediatr Diabetes 2009, 10:310-315.
90. Obrosova I.G., Drel V.R., Pacher P., et al. Oxidative-nitrosative stress and poly(ADP-ribose) polymerase (PARP) activation in experimental diabetic neuropathy: the relation is revisited. Diabetes 2005, 54:3435-3441.
91. Obrosova I.G., Xu W., Lyzogubov V.V., et al. PARP inhibition or gene deficiency counteracts intraepidermal nerve fiber loss and neuropathic pain in advanced diabetic neuropathy. Free Radic Biol Med 2008, 44:972-981.
92. Ohshiro Y., Ma R.C., Yasuda Y., et al. Reduction of diabetes-induced oxidative stress, fibrotic cytokine expression, and renal dysfunction in protein kinase Cbeta-null mice. Diabetes 2006, 55:3112-3120.
93. Oka M., Kato N. Aldose reductase inhibitors. J Enzyme Inhib 2001, 16:465-473.
94. Okopien B., Krysiak R., Herman Z.S., et al. Effects of short-term fenofibrate treatment on circulating markers of inflammation and hemostasis in patients with impaired glucose tolerance. J Clin Endocrinol Metab 2006, 91:1770-1778.
95. Oltman C.L., Davidson E.P., Coppey L.J., et al. Attenuation of vascular/neural dysfunction in Zucker rats treated with enalapril or rosuvastatin. Obesity (Silver Spring) 2008, 16:82-89.
96. Orstavik K., Jorum E. Microneurographic findings of relevance to pain in patients with erythromelalgia and patients with diabetic neuropathy. Neurosci Lett 2010, 470:180-184.
97. Pacher P., Szabo C. Role of poly(ADP-ribose) polymerase-1 activation in the pathogenesis of diabetic complications: endothelial dysfunction, as a common underlying theme. Antioxid Redox Signal 2005, 7:1568-1580.
98. Park J.Y., Ha S.W., King G.L., et al. The role of protein kinase C activation in the pathogenesis of diabetic vascular complications. Perit Dial Int 1999, 19:S222-S227.
99. Pereira Lopes F.R., Lisboa B.C., Frattini F., et al. Enhancement of sciatic-nerve regeneration after VEGF gene therapy. Neuropathol Appl Neurobiol 2011, 37:600-612.
100. Pfeifer M.A., Schumer M.P., Gelber D.A., et al. Aldose reductase inhibitors: the end of an era or the need for different trial designs?. Diabetes 1997, 46:S82-S89.
101. Pierson C.R., Zhang W., Murakawa Y., et al. Insulin deficiency rather than hyperglycemia accounts for impaired neurotrophic responses and nerve fiber regeneration in type 1 diabetic neuropathy. J Neuropathol Exp Neurol 2003, 62:260-271.
102. Polydefkis M., Hauer P., Sheth S., et al. The time course of epidermal nerve fibre regeneration: studies in normal controls and in people with diabetes, with and without neuropathy. Brain 2004, 127:1606-1615.
103. Pop-Busui R., Herman W.H., Feldman E.L., et al. DCCT and EDIC studies in type 1 diabetes: lessons for diabetic neuropathy regarding metabolic memory and natural history. Curr Diab Rep 2010, 10:276-282.
104. Pradhan A.D., Cook N.R., Buring J.E., et al. C-reactive protein is independently associated with fasting insulin in nondiabetic women. Arterioscler Thromb Vasc Biol 2003, 23:650-655.
105. Pratchayasakul W., Kerdphoo S., Petsophonsakul P., et al. Effects of high-fat diet on insulin receptor function in rat hippocampus and the level of neuronal corticosterone. Life Sci 2011, 88:619-627.
106. Price S.A., Agthong S., Middlemas A.B., et al. Mitogen-activated protein kinase p38 mediates reduced nerve conduction velocity in experimental diabetic neuropathy: interactions with aldose reductase. Diabetes 2004, 53:1851-1856.
107. Ramos K.M., Jiang Y., Svensson C.I., et al. Pathogenesis of spinally mediated hyperalgesia in diabetes. Diabetes 2007, 56:1569-1576.
108. Ratzmann K.P., Raschke M., Gander I., et al. Prevalence of peripheral and autonomic neuropathy in newly diagnosed type II (noninsulin-dependent) diabetes. J Diabet Complications 1991, 5:1-5.
109. Reasner C.A. Reducing cardiovascular complications of type 2 diabetes by targeting multiple risk factors. J Cardiovasc Pharmacol 2008, 52:136-144.
110. Reddi A.S., Jyothirmayi G.N., Leevy C.B., et al. Effect of genetic diabetes and alcohol on tissue carnitine and inositol concentrations in mice. Alcohol Alcohol 1990, 25:137-141.
111. Reddy M.A., Natarajan R. Epigenetic mechanisms in diabetic vascular complications. Cardiovasc Res 2011, 90:421-425.
112. Requena J.R., Vidal P., Cabezas-Cerrato J., et al. Aminoguanidine inhibits the modification of proteins by lipid peroxidation derived aldehydes: a possible antiatherogenic agent. Diabetes Res 1992, 20:43-49.
113. Romanovsky D., Cruz N.F., Dienel G.A., et al. Mechanical hyperalgesia correlates with insulin deficiency in normoglycemic streptozotocin-treated rats. Neurobiol Dis 2006, 24:384-394.
114. Roos M.D., Su K., Baker J.R., et al. O glycosylation of an Sp1-derived peptide blocks known Sp1 protein interactions. Mol Cell Biol 1997, 17:6472-6480.
115. Ropper A.H., Gorson K.C., Gooch C.L., et al. Vascular endothelial growth factor gene transfer for diabetic polyneuropathy: a randomized, double-blinded trial. Ann Neurol 2009, 65:386-393.
116. Ruberte J., Ayuso E., Navarro M., et al. Increased ocular levels of IGF-1 in transgenic mice lead to diabetes-like eye disease. J Clin Invest 2004, 113:1149-1157.
117. Russell J.W., Berent-Spillson A., Vincent A.M., et al. Oxidative injury and neuropathy in diabetes and impaired glucose tolerance. Neurobiol Dis 2008, 30:420-429.
118. Russell J.W., Sullivan K.A., Windebank A.J., et al. Neurons undergo apoptosis in animal and cell culture models of diabetes. Neurobiol Dis 1999, 6:347-363.
119. Schieven G.L. The biology of p38 kinase: a central role in inflammation. Curr Top Med Chem 2005, 5:921-928.
120. Schmidt A.M., Hori O., Brett J., et al. Cellular receptors for advanced glycation end products. Implications for induction of oxidant stress and cellular dysfunction in the pathogenesis of vascular lesions. Arterioscler Thromb 1994, 14:1521-1528.
121. Schubert M., Gautam D., Surjo D., et al. Role for neuronal insulin resistance in neurodegenerative diseases. Proc Natl Acad Sci U S A 2004, 101:3100-3105.
122. Setacci C., de Donato G., Setacci F., et al. Diabetic patients: epidemiology and global impact. J Cardiovasc Surg (Torino) 2009, 50:263-273.
123. Shah V.O., Dorin R.I., Sun Y., et al. Aldose reductase gene expression is increased in diabetic nephropathy. J Clin Endocrinol Metab 1997, 82:2294-2298.
124. Shimoshige Y., Enomoto R., Aoki T., et al. The involvement of aldose reductase in alterations to neurotrophin receptors and neuronal cytoskeletal protein mRNA levels in the dorsal root ganglion of streptozotocin-induced diabetic rats. Biol Pharm Bull 2010, 33:67-71.
125. Sima A.A. C-peptide and diabetic neuropathy. Expert Opin Investig Drugs 2003, 12:1471-1488.
126. Sima A.A., Ristic H., Merry A., et al. Primary preventive and secondary interventionary effects of acetyl-L-carnitine on diabetic neuropathy in the bio-breeding Worcester rat. J Clin Invest 1996, 97:1900-1907.
127. Singleton J.R., Smith A.G., Bromberg M.B., et al. Increased prevalence of impaired glucose tolerance in patients with painful sensory neuropathy. Diabetes Care 2001, 24:1448-1453.
128. Smith A.G., Singleton J.R. Impaired glucose tolerance and neuropathy. Neurologist 2008, 14:23-29.
129. Sousa M.M., Du Yan S., Fernandes R., et al. Familial amyloid polyneuropathy: receptor for advanced glycation end products-dependent triggering of neuronal inflammatory and apoptotic pathways. J Neurosci 2001, 21:7576-7586.
130. Steele J.W., Faulds D., Goa K.L., et al. Epalrestat. A review of its pharmacology, and therapeutic potential in late-onset complications of diabetes mellitus. Drugs Aging 1993, 3:532-555.
131. Stevens A. The effectiveness of putative anti-cataract agents in the prevention of protein glycation. J Am Optom Assoc 1995, 66:744-749.
132. Stevens M.J., Obrosova I.G., Cao X., et al. Effects of DL-alpha-lipoic acid on peripheral nerve conduction, blood flow, energy metabolism, and oxidative stress in experimental diabetic neuropathy. Diabetes 2000, 49:1006-1015.
133. Stevens M.J., Zhang W., Li F., et al. C-peptide corrects endoneurial blood flow but not oxidative stress in type 1 BB/Wor rats. Am J Physiol Endocrinol Metab 2004, 287:E497-E505.
134. Sugimoto K., Yasujima M., Yagihashi S., et al. Role of advanced glycation end products in diabetic neuropathy. Curr Pharm Des 2008, 14:953-961.
135. Sullivan K.A., Kim B., Feldman E.L., et al. Insulin-like growth factors in the peripheral nervous system. Endocrinology 2008, 149:5963-5971.
136. Suzuki Y., Sato J., Kawanishi M., et al. Lowered response threshold and increased responsiveness to mechanical stimulation of cutaneous nociceptive fibers in streptozotocin-diabetic rat skin in vitro: correlates of mechanical allodynia and hyperalgesia observed in the early stage of diabetes. Neurosci Res 2002, 43:171-178.
137. Sweitzer S.M., Medicherla S., Almirez R., et al. Antinociceptive action of a p38alpha MAPK inhibitor, SD-282, in a diabetic neuropathy model. Pain 2004, 109:409-419.
138. Szabo C. Roles of poly(ADP-ribose) polymerase activation in the pathogenesis of diabetes mellitus and its complications. Pharmacol Res 2005, 52:60-71.
139. Taghibiglou C., Bradley C.A., Gaertner T., et al. Mechanisms involved in cholesterol-induced neuronal insulin resistance. Neuropharmacology 2009, 57:268-276.
140. Tesfamariam B. Free radicals in diabetic endothelial cell dysfunction. Free Radic Biol Med 1994, 16:383-391.
141. Thomas T.P., Porcellati F., Kato K., et al. Effects of glucose on sorbitol pathway activation, cellular redox, and metabolism of myo-inositol, phosphoinositide, and diacylglycerol in cultured human retinal pigment epithelial cells. J Clin Invest 1994, 93:2718-2724.
142. Thornalley P.J. Glycation in diabetic neuropathy: characteristics, consequences, causes, and therapeutic options. Int Rev Neurobiol 2002, 50:37-57.
143. Thornalley P.J. Use of aminoguanidine (Pimagedine) to prevent the formation of advanced glycation endproducts. Arch Biochem Biophys 2003, 419:31-40.
144. Toth C., Rong L.L., Yang C., et al. Receptor for advanced glycation end products (RAGEs) and experimental diabetic neuropathy. Diabetes 2008, 57:1002-1017.
145. UK-PDS UK Prospective Diabetes Study 6. Complications in newly diagnosed type 2 diabetic patients and their association with different clinical and biochemical risk factors. Diabetes Res 1990, 13:1-11.
146. Villeneuve L.M., Natarajan R. The role of epigenetics in the pathology of diabetic complications. Am J Physiol Renal Physiol 2010, 299:F14-F25.
147. Vincent A.M., Edwards J.L., Sadidi M., et al. The antioxidant response as a drug target in diabetic neuropathy. Curr Drug Targets 2008, 9:94-100.
148. Vincent A.M., Feldman E.L. Control of cell survival by IGF signaling pathways. Growth Horm IGF Res 2002, 12:193-197.
149. Vincent A.M., Feldman E.L. New insights into the mechanisms of diabetic neuropathy. Rev Endocr Metab Disord 2004, 5:227-236.
150. Vincent A.M., Hayes J.M., McLean L.L., et al. Dyslipidemia-induced neuropathy in mice: the role of oxLDL/LOX-1. Diabetes 2009, 58:2376-2385.
151. Vincent A.M., Hinder L.M., Pop-Busui R., et al. Hyperlipidemia: a new therapeutic target for diabetic neuropathy. J Peripher Nerv Syst 2009, 14:257-267.
152. Vincent A.M., Kato K., McLean L.L., et al. Sensory neurons and schwann cells respond to oxidative stress by increasing antioxidant defense mechanisms. Antioxid Redox Signal 2009, 11:425-438.
153. Vincent A.M., McLean L.L., Backus C., et al. Short-term hyperglycemia produces oxidative damage and apoptosis in neurons. FASEB J 2005, 19:638-640.
154. Vincent A.M., Mobley B.C., Hiller A., et al. IGF-I prevents glutamate-induced motor neuron programmed cell death. Neurobiol Dis 2004, 16:407-416.
155. Vincent A.M., Olzmann J.A., Brownlee M., et al. Uncoupling proteins prevent glucose-induced neuronal oxidative stress and programmed cell death. Diabetes 2004, 53:726-734.
156. Vincent A.M., Russell J.W., Low P., et al. Oxidative stress in the pathogenesis of diabetic neuropathy. Endocr Rev 2004, 25:612-628.
157. Vincent A.M., Perrone L., Sullivan K.A., et al. Receptor for advanced glycation end products activation injures primary sensory neurons via oxidative stress. Endocrinology 2007, 148:548-558.
158. Vinik A.I., Anandacoomaraswamy D., Ullal J., et al. Antibodies to neuronal structures: innocent bystanders or neurotoxins?. Diabetes Care 2005, 28:2067-2072.
159. Vinik A.I., Bril V., Kempler P., et al. Treatment of symptomatic diabetic peripheral neuropathy with the protein kinase C beta-inhibitor ruboxistaurin mesylate during a 1-year, randomized, placebo-controlled, double-blind clinical trial. Clin Ther 2005, 27:1164-1180.
160. Vinik A., Ullal J., Parson H.K., et al. Diabetic neuropathies: clinical manifestations and current treatment options. Nat Clin Pract Endocrinol Metab 2006, 2:269-281.
161. Walcher D., Aleksic M., Jerg V., et al. C-peptide induces chemotaxis of human CD4-positive cells: involvement of pertussis toxin-sensitive G-proteins and phosphoinositide 3-kinase. Diabetes 2004, 53:1664-1670.
162. Walcher D., Marx N. C-Peptide in the vessel wall. Rev Diabet Stud 2009, 6:180-186.
163. Walwyn W.M., Matsuka Y., Arai D., et al. HSV-1-mediated NGF delivery delays nociceptive deficits in a genetic model of diabetic neuropathy. Exp Neurol 2006, 198:260-270.
164. Wang X.L., Zhang H.M., Chen S.R., et al. Altered synaptic input and GABAB receptor function in spinal superficial dorsal horn neurons in rats with diabetic neuropathy. J Physiol 2007, 579:849-861.
165. Way K.J., Chou E., King G.L., et al. Identification of PKC-isoform-specific biological actions using pharmacological approaches. Trends Pharmacol Sci 2000, 21:181-187.
166. Wiggin T.D., Sullivan K.A., Pop-Busui R., et al. Elevated triglycerides correlate with progression of diabetic neuropathy. Diabetes 2009, 58:1634-1640.
167. Wittmack E.K., Rush A.M., Hudmon A., et al. Voltage-gated sodium channel Nav1.6 is modulated by p38 mitogen-activated protein kinase. J Neurosci 2005, 25:6621-6630.
168. Woodman R.J., Chew G.T., Watts G.F., et al. Mechanisms, significance and treatment of vascular dysfunction in type 2 diabetes mellitus: focus on lipid-regulating therapy. Drugs 2005, 65:31-74.
169. Yan S.F., Ramasamy R., Naka Y., et al. Glycation, inflammation, and RAGE: a scaffold for the macrovascular complications of diabetes and beyond. Circ Res 2003, 93:1159-1169.
170. Yeh C.H., Sturgis L., Haidacher J., et al. Requirement for p38 and p44/p42 mitogen-activated protein kinases in RAGE-mediated nuclear factor-kappaB transcriptional activation and cytokine secretion. Diabetes 2001, 50:1495-1504.
171. Yorek M.A., Dunlap J.A., Ginsberg B.H., et al. myo-Inositol metabolism in 41A3 neuroblastoma cells: effects of high glucose and sorbitol levels. J Neurochem 1987, 48:53-61.
172. Young M.J., Veves A., Smith J.V., et al. Restoring lower limb blood flow improves conduction velocity in diabetic patients. Diabetologia 1995, 38:1051-1054.
173. Young L.H., Ikeda Y., Scalia R., et al. C-peptide exerts cardioprotective effects in myocardial ischemia-reperfusion. Am J Physiol Heart Circ Physiol 2000, 279:H1453-H1459.
174. Zanone M.M., Burchio S., Quadri R., et al. Autonomic function and autoantibodies to autonomic nervous structures, glutamic acid decarboxylase and islet tyrosine phosphatase in adolescent patients with IDDM. J Neuroimmunol 1998, 87:1-10.
175. Zhang L., Yu C., Vasquez F.E., et al. Hyperglycemia alters the schwann cell mitochondrial proteome and decreases coupled respiration in the absence of superoxide production. J Proteome Res 2010, 9:458-471.
176. Ziegler D., Mayer P., Wiefels K., et al. Assessment of small and large fiber function in long-term type 1 (insulin-dependent) diabetic patients with and without painful neuropathy. Pain 1988, 34:1-10.
177. Zochodne D.W., Levy D. Nitric oxide in damage, disease and repair of the peripheral nervous system. Cell Mol Biol (Noisy-le-grand) 2005, 51:255-267.